Who are Topical calcineurin inhibitors's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sandimmune, CYCLOSPORINE, Tacrolimus (Prograf®), Cyclosporins/Tacrolimus, Ciclosporin and Mycophenolate-mofetil, CsA+MMF+CS.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/topical-calcineurin-inhibitors.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Topical calcineurin inhibitors — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Topical calcineurin inhibitors (Topical calcineurin inhibitors) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: calcineurin inhibitor. Area: Immunology.

phase 3 calcineurin inhibitor calcineurin Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Topical calcineurin inhibitors (Topical calcineurin inhibitors) — Sanofi. Topical calcineurin inhibitors block the action of calcineurin, a protein involved in the activation of T-cells, thereby reducing inflammation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Topical calcineurin inhibitors TARGET	Topical calcineurin inhibitors	Sanofi	phase 3	calcineurin inhibitor	calcineurin
Sandimmune	cyclosporine	Novartis AG (originally Sandoz)	marketed	Calcineurin inhibitor (immunosuppressant)	Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2	1983-11-14
CYCLOSPORINE	CYCLOSPORINE		marketed	Calcineurin Inhibitor Immunosuppressant [EPC]	calcineurin	1983-01-01
Tacrolimus (Prograf®)	Tacrolimus (Prograf®)	Astellas Pharma Inc	marketed	Calcineurin inhibitor	Calcineurin (via FKBP12 binding)
Cyclosporins/Tacrolimus	Cyclosporins/Tacrolimus	University of Minnesota	marketed	Calcineurin inhibitor	Calcineurin
Ciclosporin and Mycophenolate-mofetil	Ciclosporin and Mycophenolate-mofetil	University of Giessen	marketed	Immunosuppressant combination	Calcineurin (ciclosporin); IMPDH type II (mycophenolate mofetil)
CsA+MMF+CS	CsA+MMF+CS	Pfizer	marketed	Immunosuppressive combination therapy	Calcineurin (CsA); IMPDH type II (MMF); glucocorticoid receptor (CS)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-11-03 — Sandimmune · 8298568 · Formulation · US
2029-06-02 — Sandimmune · 9132071 · Formulation · US
2030-12-13 — Sandimmune · 8614178 · Formulation · US
2031-02-25 — Sandimmune · 8292129 · Formulation · US
2032-04-16 — Sandimmune · 8561859 · Formulation · US
2033-08-23 — Sandimmune · 8980839 · Formulation · US
2033-08-23 — Sandimmune · 10441630 · Formulation · US
2033-08-23 — Sandimmune · 9937225 · Formulation · US
2034-02-07 — Sandimmune · 9676525 · Formulation · US
2034-05-11 — Sandimmune · 9669974 · Formulation · US
2036-09-29 — Sandimmune · 12496326 · Method of Use · US
2037-02-28 — Sandimmune · 11951153 · Method of Use · US
2037-02-28 — Sandimmune · 10918694 · Formulation · US
2037-09-22 — Sandimmune · 10813976 · Formulation · US
2038-11-20 — Sandimmune · 11154513 · Formulation · US
2039-10-11 — Sandimmune · 11413323 · Method of Use · US
2042-04-01 — Sandimmune · 12059449 · Formulation · US

Sponsor landscape (calcineurin inhibitor class)

Sanofi · 2 drugs in this class
Fovea Pharmaceuticals SA · 1 drug in this class
Galderma R&D · 1 drug in this class
Glenmark Pharmaceuticals Ltd. India · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Topical calcineurin inhibitors — Competitive Intelligence Brief. https://druglandscape.com/ci/topical-calcineurin-inhibitors. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab